Ardena (GHO Capital Portfolio) Acquires Idifarma from Suanfarma and Sodena

GHO Capital Acquires Ardena, a European Early‑Stage CDMO

January 9, 2020

Pharmaceuticals

GHO Capital Partners LLP has acquired Ardena, a Belgium‑headquartered contract development and manufacturing organisation (CDMO) focused on early‑phase drug development, from Mentha Capital and existing management. GHO will partner with Ardena's management to accelerate international growth, broaden the company’s service offering and build a fully integrated early‑stage CDMO platform through organic and inorganic expansion.

Ardena Acquires Catalent's Somerset, New Jersey Drug Product Facility

October 14, 2024

Pharmaceuticals

Ardena, a GHO Capital-backed CDMO, has signed a definitive agreement to acquire Catalent's FDA-approved drug product manufacturing facility in Somerset, New Jersey. The acquisition — expected to close in early 2025 subject to approvals — expands Ardena's US footprint and downstream capabilities in oral solid dosage manufacturing and bioanalytical services.

Adare Pharma Solutions Acquires Frontida BioPharm

December 1, 2021

Pharmaceuticals

Adare Pharma Solutions, a PE-backed contract development and manufacturing organization (CDMO), has acquired Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The deal expands Adare’s capabilities—including high-potency compound handling and packaging services—and increases its manufacturing footprint; Adare is backed by Thomas H. Lee Partners and Frazier Healthcare Partners.

Astorg Acquires Pharmaceutical CDMO CordenPharma from ICIG

May 2, 2022

Pharmaceuticals

Astorg has signed a binding agreement to acquire CordenPharma, a global contract development and manufacturing organization (CDMO) focused on APIs, excipients and drug products, from International Chemical Investors Group (ICIG). CordenPharma employs over 2,600 people across 11 manufacturing sites and an R&D laboratory in Europe and the US; the founders will reinvest alongside Astorg. The transaction is subject to customary regulatory approvals and terms were not disclosed.

Fagron Acquires Purifarma (Brazil)

January 6, 2026

Pharmaceuticals

Fagron has completed the acquisition of Purifarma in Brazil following CADE approval, strengthening Fagron's scale in Essentials and advancing its buy-and-build strategy. Purifarma is a large-scale distributor/importer of pharmaceutical, food and cosmetic inputs; the transaction carries an enterprise value of approximately R$250 million and is expected to deliver product-mix improvements, access to industrial customers and purchasing synergies across Latin America.

Fagron Acquires Purifarma in Brazil

January 6, 2026

Pharmaceuticals

Fagron has completed the acquisition of Purifarma, a large-scale pharmaceutical essentials business in Brazil, for an enterprise value of approximately R$250 million. The deal strengthens Fagron's scale and procurement position in Latin America and supports the Group's buy-and-build strategy to expand its pharmaceutical compounding and essentials platform.